Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3142-3152

  Hasija, Rachana ^a   Pistorio, Angela ^a   Ravelli, Angelo ^a   Demirkaya, Erkan ^a   Khubchandani, Raju ^b   Guseinova, Dinara ^a   Malattia, Clara ^a   Canhao, Helena ^c   Harel, Liora ^d   Foell, Dirk ^e   Wouters, Carine ^f   De Cunto, Carmen ^g   Huemer, Christian ^h   Kimura, Yukiko ⁱ   Mangge, Harald ^j   Minetti, Carlo ^a   Nordal, Ellen Berit ^k   Philippet, Pierre ^l   Garozzo, Rosaria ^m   Martini, Alberto ^a   Ruperto, Nicolino ^a   more..

^a UNIVERSITY OF GENOA   (Italy)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^c UNIVERSITY OF LISBON   (Portugal)

^d SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^h Landeskrankenhaus Bregenz   (Austria)

ⁱ HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^l Centre Hospitalier Chretien   (Belgium)

^m UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

ADOLESCENT; ARTICLE; CENTRAL AMERICA; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG PULSE THERAPY; EASTERN EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SOUTH AMERICA; TREATMENT DURATION; TREATMENT RESPONSE; WESTERN EUROPE;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053477558     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30475     Document Type: Article

References (44)

1. Cassidy JT, Petty RE, Laxer RM, Lindsley CB,. Textbook of pediatric rheumatology. 6th ed. Philadelphia: W.B. Saunders Company; 2010.
2. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 300-5. (Pubitemid 36682395)
3. Feldman BM, Rider LG, Reed AM, Pachman LM,. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-12. (Pubitemid 351890413)
4. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 63-72.
5. Ramanan AV, Feldman BM,. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28: 833-57. (Pubitemid 36008555)
6. Ramanan AV, Feldman BM,. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002; 14: 658-62. (Pubitemid 35191552)
7. Rider LG,. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 935-77. (Pubitemid 36008559)
8. Ruperto N, Martini A,. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004; 16: 566-70. (Pubitemid 39128326)
9. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 1452-9. (Pubitemid 37508918)
10. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Pediatric Rheumatology International Trial Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 4-13. (Pubitemid 351171873)
11. Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62: 1533-41.
12. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
13. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
14. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis isease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiophatic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis Rheum 1997; 40: 1976-83. (Pubitemid 27494657)
15. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213-9. (Pubitemid 30263608)
16. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004; 51: 365-70. (Pubitemid 38725134)
17. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595-603. (Pubitemid 38608082)
18. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM,. Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 7-15. (Pubitemid 36286124)
19. Singh G, Athreya BH, Fries JF, Goldsmith DP,. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 1761-9. (Pubitemid 24371878)
20. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al, for the Paediatric Rheumatology International Trials Organisation. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001; 19: S1-9. (Pubitemid 33730178)
21. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. J Rheumatol 2001; 28: 1106-11. (Pubitemid 32422597)
22. Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira SJ, Marcantoni MB, et al, for the Paediatric Rheumatology International Trials Organisation. Health-related quality of life of patients with juvenile dermatomyositis: results from the Paediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009; 61: 509-17.
23. Landgraf JM, Abetz L, Ware JE,. The CHQ user's manual. 1st ed. Boston: The Health Institute, New England Medical Center; 1996.
24. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al, and the International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30: 603-17. (Pubitemid 36301957)
25. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al, and the International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1262-73.
26. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90. (Pubitemid 38924407)
27. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607-15. (Pubitemid 41369088)
28. Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM,. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008; 59: 989-95. (Pubitemid 351990996)
29. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM,. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 59: 222-6. (Pubitemid 351272958)
30. Fischer TJ, Rachelefsky GS, Klein RB, Paulus HE, Stiehm ER,. Childhood dermatomyositis and polymyositis: treatment with methotrexate and prednisone. Am J Dis Child 1979; 133: 386-9. (Pubitemid 9212624)
31. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG,. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143-9.
32. Al-Mayouf S, Al-Mazyed A, Bahabri S,. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 138-41. (Pubitemid 30236145)
33. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 3570-8. (Pubitemid 41612226)
34. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436-43. (Pubitemid 28005149)
35. Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11: 203-8. (Pubitemid 23155993)
36. Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 1063-6. (Pubitemid 19123068)
37. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000. (Pubitemid 24015043)
38. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW,. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513-5. (Pubitemid 17096184)
39. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM,. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498-503.
40. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM,. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-72.
41. Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF,. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr 2010; 156: 302-7.
42. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey. J Rheumatol 2010; 37: 1953-61.
43. Pincus T, Stein CM,. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? J Rheumatol 1995; 22: 1611-7.
44. Pincus T, Sokka T,. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004; 63: 32-9.